Skip to main content
. Author manuscript; available in PMC: 2016 Jul 1.
Published in final edited form as: Nanomedicine. 2015 Mar 16;11(5):1169–1178. doi: 10.1016/j.nano.2015.02.016

Figure 2.

Figure 2

A) Example HPLC chromatograms of fluorescently labeled nanoparticles; the peak area for the encapsulated fluorescent molecule is directly proportional to the size of the hydrophilic corona DSPE–PEG2000–SS–biotin > DSPE–PEG2000–biotin > DSPE– PEG2000–NH2. B) Plasma concentration–time profiles of nanoparticles in male Sprague Dawley rats following a single oral administration of fluorescently labeled nanoparticles equivalent to 1.42 mg/kg: DSPE–PEG2000–NH2 (◇); DSPE–PEG2000–biotin (□), and DSPE–PEG2000–SS–biotin (▲) (mean ± SD, n = 6). C) Pharmacokinetic parameters of nanoparticles following a single dose based on noncompartmental calculation (mean ± SD, n = 6). D) Different behavior of intestinally processed and unprocessed DSPE–PEG2000–SS– biotin nanoparticles: 1, in the presence of 0.5 M glutathione, the processed nanoparticles are not released from the complex with avidin–FITC; 2, unprocessed nanoparticles are released from the complex with avidin–FITC in the presence of glutathione.